The long process of HIV-1 integrase inhibitor discovery and development can be attributed
to both the complexity of HIV-1 integration and poor 'integration'of these researches into …

HIV-1 integrase is a promising therapeutic target for the development of drugs to treat HIV
infection. Aryl diketo-based analogs, disclosed independently by scientists from Merck and …

AIDS is currently treated with a combination therapy of reverse transcriptase and protease
inhibitors. Recently, the FDA approved a drug targeting HIV-1 entry into cells. There are …

Background: HIV-1 integrase (IN) represents a therapeutically advantageous viral target to
treat HIV/AIDS in the clinic. Over a decade of progress in the field has resulted in IN inhibitor …

HIV-1 integrase (IN) is an essential enzyme for retroviral replication. It is involved in the
integration of HIV DNA into host chromosomal DNA. The unique properties of IN makes it an …

From the discovery of HIV-1 integrase (IN) inhibitors using enzyme-based assays in 1992, it
has taken 15 years to achieve success in human clinical trials. Currently available …

HIV‐1 integrase is a protein of Mr 32 000 encoded at the 3′‐end of the pol gene.
Integration of HIV DNA into the host cell chromosomal DNA apparently occurs by a carefully …

The integration of viral cDNA into the host genome is an essential step in the HIV‐1‐life
cycle and is mediated by the virally encoded enzyme, integrase (IN). Inhibition of this …

Integration of viral DNA into host cell chromosomal DNA to form a provirus is an essential
step in the viral life cycle. This process is mediated by integrase (IN), a 32 KDa viral enzyme …

Validation of integrase as a suitable therapeutic target for the development of drugs against
HIV infection; discovery of diketo acid derivatives as bona fide inhibitors of integrase and the …